<DOC>
	<DOCNO>NCT00421395</DOCNO>
	<brief_summary>This open label , multiple center , non-randomized , dose-escalation Phase I/II trial , design evaluate safety effectiveness repeat , outpatient regimen utilize IMMU-hLL2 intact monoclonal antibody IgG label different dos 90Y treatment patient B-cell lymphoma ( NHL ) .</brief_summary>
	<brief_title>Safety Study NHL With 90Y-hLL2 IgG</brief_title>
	<detailed_description>90Y-labeled hLL2 administer accord schedule base upon whether patient prior high-dose chemotherapy marrow stem cell transplant . Patients indolent aggressive type NHL enrol dose level without segregation . However , conclusion trial , maximum tolerate dose ( MTD ) define , minimum number 6 patient indolent NHL , 6 patient aggressive NHL , 6 patient &gt; 25 % bone marrow involvement study dose level .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>All patient must histologic cytological diagnosis Bcell lymphoma , fail least one regimen standard chemotherapy . All histologic grade nonHodgkin 's lymphoma ( NHL ) eligible study . Patients must &gt; 18 year age Measurable disease CT , least one lesion &gt; 1.5 cm one dimension less 25 % bone marrow involvement determine bone marrow biopsy Patient must great 15 % cellularity bone marrow . Patients must least 4 week beyond major surgery . Patients must least 4 week beyond radiation therapy index lesion must recover radiation induced toxicity . Patients must least 4 week beyond prior chemotherapy and/or immunotherapy , 2weeks corticosteroid , blood count must within eligibility criterion . Corticosteroids may , however , give concomitantly use treat adrenal insufficiency Patients must performance status 70 great Karnofsky scale equivalent ECOG 01 ( See Appendix A ) minimal life expectancy 6 month . Patients must able give cognizant inform consent . Patients significant concurrent medical complication include severe anorexia , nausea vomit judgement Investigator could affect patient 's ability tolerate complete study . Patients metastasis brain . Patients extensive irradiation 25 % red marrow exclude , except total body irradiation context bone marrow stem cell transplantation regimen subsequent engraftment functional marrow ( i.e. , result normal peripheral blood count ) . Subjects received external radiation specific organ area maximum tolerated level also exclude . Women test positive pregnancy . Patients splenomegaly . Patients &gt; 4 treatment regimen prior protocol , include chemotherapy , radiotherapy and/or immunotherapy . Patients prior radioimmunotherapy treatment ( unless retreatment protocol ) . Patients receive rituximab within 3 month , unless progress treatment . Patients &lt; 50 % LVEF require MUGA 2D ECHO . Patients &lt; 60 % predict value require pulmonary function test . Patients active Hepatitis B C know HIV positive . Patients another primary malignancy ( except basal/squamous cell carcinoma skin carcinoma insitu cervix . Patients serious medical , surgical , psychiatric history , unless currently stable well control , without significant increase treatment medication least 30 day precede study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>NHL</keyword>
	<keyword>B-cell NHL</keyword>
	<keyword>Non-Hodgkins lymphoma</keyword>
</DOC>